Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/64834
Type: Conference paper
Title: Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial
Author: Yeung, D.
Osborn, M.
White, D.
Branford, S.
Haswell, L.
Slader, C.
Issa, S.
Hiwase, D.
Hertzberg, M.
Schwarer, A.
Filshie, R.
Arthur, C.
Kwan, Y.
Forsyth, C.
Ross, D.
Mills, A.
Grigg, A.
Hughes, T.
Citation: Blood, 2010; 116 (21), Abstract 209
Issue Date: 2010
Conference Name: Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
Organisation: Australasian Leukaemia & Lymphoma Group
Statement of
Responsibility: 
David T. Yeung, Michael Osborn, Deborah L. White, Susan Branford, Lauren Haswell, Cassandra Slader, Samar Issa, Devendra K. Hiwase, Mark S. Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg and Timothy Hughes and on behalf of ALLG
Description: Oral session ASH Annual Meeting Abstracts: 52nd Annual Meeting of the American Society of Hematology (ASH), Orlando, FL, December 4-7, 2010
Rights: © 2010 American Society of Hematology
RMID: 0020102994
Description (link): http://abstracts.hematologylibrary.org/content/vol116/issue21/
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.